TMS（4891）株式概要株式会社トムスは、医薬品、医薬部外品、原薬、医療機器、医療用品の研究開発、製造、販売を行っています。 詳細4891 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( ¥0 )今後3年間の収益は年平均21.1%減少すると予測されている。 意味のある時価総額がありません ( ¥6B )現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見る4891 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueJP¥Current PriceJP¥138.00該当なし内在価値ディスカウントEst. Revenue$PastFuture-934m2b2016201920222025202620282031Revenue -JP¥0.00008Earnings -JP¥0.00002AdvancedSet Fair ValueView all narrativesTMS Co., Ltd. 競合他社Kohjin BioSymbol: TSE:177AMarket cap: JP¥6.3bNoile-Immune BiotechSymbol: TSE:4893Market cap: JP¥5.6bBrightPath BiotherapeuticsSymbol: TSE:4594Market cap: JP¥7.0bModalis TherapeuticsSymbol: TSE:4883Market cap: JP¥5.3b価格と性能株価の高値、安値、推移の概要TMS過去の株価現在の株価JP¥138.0052週高値JP¥185.0052週安値JP¥122.00ベータ0.521ヶ月の変化-6.76%3ヶ月変化-2.82%1年変化-10.97%3年間の変化-37.27%5年間の変化n/aIPOからの変化-82.05%最新ニュースNew Risk • Apr 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 21% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Market cap is less than US$100m (JP¥6.32b market cap, or US$39.8m).New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.0b net loss in 3 years). Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (JP¥6.14b market cap, or US$39.1m).お知らせ • Feb 13TMS Co., Ltd., Annual General Meeting, Mar 27, 2026TMS Co., Ltd., Annual General Meeting, Mar 27, 2026.New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.0b net loss in 3 years). Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (JP¥6.82b market cap, or US$43.1m).分析記事 • Jan 07Here's Why We're Not At All Concerned With TMS' (TSE:4891) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Dec 24TMS Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026TMS Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026最新情報をもっと見るRecent updatesNew Risk • Apr 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 21% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Market cap is less than US$100m (JP¥6.32b market cap, or US$39.8m).New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.0b net loss in 3 years). Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (JP¥6.14b market cap, or US$39.1m).お知らせ • Feb 13TMS Co., Ltd., Annual General Meeting, Mar 27, 2026TMS Co., Ltd., Annual General Meeting, Mar 27, 2026.New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.0b net loss in 3 years). Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (JP¥6.82b market cap, or US$43.1m).分析記事 • Jan 07Here's Why We're Not At All Concerned With TMS' (TSE:4891) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Dec 24TMS Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026TMS Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026Price Target Changed • Oct 16Price target decreased by 18% to JP¥620Down from JP¥760, the current price target is provided by 1 analyst. New target price is 300% above last closing price of JP¥155. Stock is down 15% over the past year. The company is forecast to post a net loss per share of JP¥27.97 next year compared to a net loss per share of JP¥16.37 last year.お知らせ • Aug 26TMS Co., Ltd. to Report Q2, 2026 Results on Oct 15, 2025TMS Co., Ltd. announced that they will report Q2, 2026 results on Oct 15, 2025New Risk • Jul 22New major risk - Revenue and earnings growthEarnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Market cap is less than US$100m (JP¥7.49b market cap, or US$50.8m).お知らせ • May 24TMS Co., Ltd. to Report Q1, 2026 Results on Jul 15, 2025TMS Co., Ltd. announced that they will report Q1, 2026 results on Jul 15, 2025お知らせ • Apr 25TMS Co., Ltd. Submits CTN for Phase II/III Orion Study Japan Cohort of JX10 to PMDATMS Co., Ltd. announced that the Company has submitted a Clinical Trial Plan Notification (CTN) to the Pharmaceuticals and Medical Devices Agency ("PMDA") for ORION (Optimizing Reperfusion to Improve Outcomes and Neurologic Function), the global registrational study conducted by Corxel Pharmaceuticals Limited (CORXEL) including Japan cohort, that will investigate the effects of JX10 (also known as TMS-007) on functional recovery in acute ischemic stroke (AIS) patients, who present within 4.5 to 24 hours from "last known well". The impact of this matter on the Company's financial results of this fiscal year is minor.Breakeven Date Change • Apr 14No longer forecast to breakevenThe analyst covering TMS no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of JP¥369.0m in 2026. New forecast suggests the company will make a loss of JP¥961.0m in 2028.Breakeven Date Change • Apr 12No longer forecast to breakevenThe analyst covering TMS no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of JP¥369.0m in 2026. New forecast suggests the company will make a loss of JP¥961.0m in 2028.お知らせ • Apr 11TMS Co., Ltd., Annual General Meeting, May 29, 2025TMS Co., Ltd., Annual General Meeting, May 29, 2025.New Risk • Mar 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.1b net loss in 3 years). Market cap is less than US$100m (JP¥7.14b market cap, or US$48.1m).お知らせ • Feb 26TMS Co., Ltd. to Report Fiscal Year 2025 Results on Apr 11, 2025TMS Co., Ltd. announced that they will report fiscal year 2025 results on Apr 11, 2025分析記事 • Feb 21We Think TMS (TSE:4891) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...お知らせ • Feb 21TMS Co., Ltd. Provided Notice on the Status of JX10 (TMS-007) Clinical Trial Application in ChinaTMS Co., Ltd. announced that Corxel Pharmaceuticals announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the PRC (NMPA) has approved the Clinical Trial Application (CTA) for ORION (Optimizing Reperfusion to Improve Outcomes and Neurologic Function), the global registrational study including China cohort, that will investigate the effects of JX10 (TMS-007) on functional recovery in acute ischemic stroke (AIS) patients, who present within 4.5 to 24 hours from "last known well". The Company plans to participate in the global study as partner in Japan. About TMS-007(JX10) TMS-007 (JX10) is an investigational drug candidate for the treatment of acute cerebral infarction (AIS), and its mechanism of action is both thrombolytic and anti-inflammatory. The important thing in the treatment strategy for acute cerebral infarction is to restore blood flow as soon as possible after the onset of symptoms. TMS-007 (JX10) extends the short treatment period of administration within 4.5 hours after the onset of symptoms, which is the current standard of treatment, and may provide treatment opportunities to many patients. In a Phase II clinical trial conducted by our company in Japan, subjects administered TMS-007 (JX10) showed significantly improved clinical outcomes (no symptoms at all or symptoms but able to work without obvious impairment) after 90 days compared to placebo. This result was also confirmed by angiographic findings. TMS-007 (JX10) is currently undergoing a global study to further evaluate its efficacy and safety for the treatment of acute cerebral infarction by CORXEL.お知らせ • Nov 27TMS Co., Ltd. to Report Q3, 2025 Results on Jan 14, 2025TMS Co., Ltd. announced that they will report Q3, 2025 results on Jan 14, 2025分析記事 • Oct 24Here's Why We're Not Too Worried About TMS' (TSE:4891) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...New Risk • Oct 11New major risk - Revenue and earnings growthEarnings have declined by 35% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (JP¥7.38b market cap, or US$49.6m).お知らせ • Aug 23TMS Co., Ltd. to Report Q2, 2025 Results on Oct 15, 2024TMS Co., Ltd. announced that they will report Q2, 2025 results on Oct 15, 2024New Risk • Jul 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.4% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (JP¥10.2b market cap, or US$63.4m).分析記事 • Jun 24We're Not Very Worried About TMS' (TSE:4891) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...お知らせ • Jun 19TMS Co., Ltd. Announces Dosing to the First Subject in TMS-008 Phase I Clinical TrialTMS Co., Ltd. announced that the first subject was dosed on June 19 in the Phase I clinical trial (Phase I single-dose, dose escalation study of TMS-008 in healthy adult male subjects; the Study) of TMS-008, which is being developed as a potential treatment for acute kidney injury. The results of previous non-clinical studies have confirmed the efficacy and safety of TMS-008 in the non-clinical phase of the study. In this Study, TMS-008 will be administered to healthy adult male subjects in escalating doses to confirm safety, tolerability, and pharmacokinetics in humans. The study will be conducted at the University of Tokyo Hospital. All subjects will be administered and observed by the end of this fiscal year, and the first readout is scheduled in the first quarter of fiscal year 2025. TMS-008 is a compound of SMTP (Stachybotrys microspora triprenyl phenol) family compounds derived from a type of black mold. The compound has strong anti-inflammatory and antioxidant activity by inhibiting soluble epoxide hydrolase (sEH) and is expected to have potential as a treatment for acute kidney injury.お知らせ • May 27TMS Co., Ltd. to Report Q1, 2025 Results on Jul 12, 2024TMS Co., Ltd. announced that they will report Q1, 2025 results on Jul 12, 2024お知らせ • Apr 14TMS Co., Ltd., Annual General Meeting, May 28, 2024TMS Co., Ltd., Annual General Meeting, May 28, 2024.お知らせ • Mar 01TMS Co., Ltd. Submits Clinical Trial Plan Notification for TMS-008 Phase I Clinical Trial in JapanTMS Co., Ltd. announced that the Company has submitted a Clinical Trial Plan Notification to the Pharmaceuticals and Medical Devices Agency ("PMDA") to start Phase I clinical trial (the "Trial") for TMS-008, which is under development for acute kidney injury and other indications. This is the First-In-Human study of TMS-008, in which TMS-008 will be administered incrementally to healthy adult male subjects to evaluate the pharmacokinetics, pharmacodynamics, and safety of TMS-008. The Trial is scheduled to begin after a 30-day investigation period by the PMDA. TMS-008 is a small molecule compound belonging to the SMTP (stachybotrys microspora triprenyl phenol) compound family derived from black mold, as TMS-007/JX10, expected to have potential as a therapeutic agent for acute kidney injury (AKI) with its anti-inflammatory activity based on soluble epoxide hydrolase (sEH) inhibition as well as antioxidant activity. AKI is an indication in which renal function rapidly declines over a period of hours to days, and no drug has been approved for treatment of AKI to date. AKI can be caused by a variety of reasons, including cardiac surgery and drug side effects. In a study of patients who underwent coronary artery bypass surgery or heart valve surgery, 43% of patients developed acute kidney injury after surgery, and the mortality rate within 30 days was reported to be as high as 20%. Due to these, it is expected there is a significant unmet medical need for effective therapeutic agents for AKI. This matter will have no impact on the Company's financial results.お知らせ • Feb 23TMS Co., Ltd. to Report Fiscal Year 2024 Results on Apr 12, 2024TMS Co., Ltd. announced that they will report fiscal year 2024 results on Apr 12, 2024New Risk • Feb 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (JP¥11.3b market cap, or US$77.3m).お知らせ • Feb 01TMS Co., Ltd. announced that it has received ¥684.324069 million in fundingOn January 31, 2024, TMS Co., Ltd. closed the transaction.New Risk • Jan 17New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 23% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Market cap is less than US$100m (JP¥10.3b market cap, or US$69.7m).お知らせ • Jan 13TMS Co., Ltd. announced that it expects to receive ¥684.324069 million in fundingTMS Co., Ltd. announced a private placement to issue 3,659,487 shares at a issue price 187 yen per share for a gross proceeds JPY 684,324,069 on January 11, 2024. The transaction included participation from RTW Master Fund, Ltd for 2,083,830 shares, RTW Innovation Master Fund, Ltd for 1,524,886 shares and RTW Biotech Opportunities Ltd for 50,771 shares. The transaction is expected to close on January 31, 2024.お知らせ • Nov 23TMS Co., Ltd. to Report Q3, 2024 Results on Jan 15, 2024TMS Co., Ltd. announced that they will report Q3, 2024 results on Jan 15, 2024New Risk • Oct 15New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: JP¥734m Forecast net loss in 3 years: JP¥325m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥325m net loss in 3 years). Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (JP¥9.04b market cap, or US$60.5m).お知らせ • Aug 09TMS Co., Ltd. to Report Q2, 2024 Results on Oct 13, 2023TMS Co., Ltd. announced that they will report Q2, 2024 results on Oct 13, 2023お知らせ • May 26TMS Co., Ltd. to Report Q1, 2024 Results on Jul 14, 2023TMS Co., Ltd. announced that they will report Q1, 2024 results on Jul 14, 2023お知らせ • Nov 27TMS Co., Ltd. to Report Q3, 2023 Results on Jan 13, 2023TMS Co., Ltd. announced that they will report Q3, 2023 results on Jan 13, 2023お知らせ • Nov 23TMS Co., Ltd. has completed an IPO in the amount of ¥2.499971 billion.TMS Co., Ltd. has completed an IPO in the amount of ¥2.499971 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,145,400 Price\Range: ¥670 Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,585,900 Price\Range: ¥670 Transaction Features: Rule 144A; Sponsor Backed Offering株主還元4891JP BiotechsJP 市場7D-1.4%-6.8%-0.5%1Y-11.0%-12.9%41.3%株主還元を見る業界別リターン: 4891過去 1 年間で-12.9 % の収益を上げたJP Biotechs業界を上回りました。リターン対市場: 4891は、過去 1 年間で41.3 % のリターンを上げたJP市場を下回りました。価格変動Is 4891's price volatile compared to industry and market?4891 volatility4891 Average Weekly Movement6.1%Biotechs Industry Average Movement9.4%Market Average Movement5.0%10% most volatile stocks in JP Market9.7%10% least volatile stocks in JP Market2.5%安定した株価: 4891 、 JP市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 4891の 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200518Takuro Wakabayashiwww.tms-japan.co.jp株式会社トムスは、医薬品、医薬部外品、原薬、医療機器、医療用品の研究開発、製造、販売を行っています。同社は、急性虚血性脳梗塞治療薬として臨床第2a相試験を終了した血栓溶解作用と抗炎症・抗酸化作用を有するスタキボトリスミクロスポラ・トリプレニルフェノール（SMTP）複合体TMS-007と、急性腎障害や癌性悪液質などの炎症性合併症を適応症として非臨床開発中の抗炎症・抗酸化作用を有するSMTP複合体TMS-008を開発している。また、前臨床開発中の製品候補であるTMS-009も開発中である。さらに、同社は北海道大学と共同研究を行い、新薬候補化合物の新薬としての可能性を評価している。株式会社TMSは2005年に設立され、日本の府中に本社を置いている。もっと見るTMS Co., Ltd. 基礎のまとめTMS の収益と売上を時価総額と比較するとどうか。4891 基礎統計学時価総額JP¥6.28b収益（TTM）-JP¥700.90m売上高(TTM)n/a0.0xP/Sレシオ-9.0xPER（株価収益率4891 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4891 損益計算書（TTM）収益JP¥0売上原価JP¥0売上総利益JP¥0その他の費用JP¥700.90m収益-JP¥700.90m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-15.41グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%4891 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 19:34終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TMS Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Miyabi YamakitaJefferies LLC
New Risk • Apr 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 21% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Market cap is less than US$100m (JP¥6.32b market cap, or US$39.8m).
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.0b net loss in 3 years). Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (JP¥6.14b market cap, or US$39.1m).
お知らせ • Feb 13TMS Co., Ltd., Annual General Meeting, Mar 27, 2026TMS Co., Ltd., Annual General Meeting, Mar 27, 2026.
New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.0b net loss in 3 years). Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (JP¥6.82b market cap, or US$43.1m).
分析記事 • Jan 07Here's Why We're Not At All Concerned With TMS' (TSE:4891) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Dec 24TMS Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026TMS Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026
New Risk • Apr 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 21% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Market cap is less than US$100m (JP¥6.32b market cap, or US$39.8m).
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.0b net loss in 3 years). Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (JP¥6.14b market cap, or US$39.1m).
お知らせ • Feb 13TMS Co., Ltd., Annual General Meeting, Mar 27, 2026TMS Co., Ltd., Annual General Meeting, Mar 27, 2026.
New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.0b net loss in 3 years). Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (JP¥6.82b market cap, or US$43.1m).
分析記事 • Jan 07Here's Why We're Not At All Concerned With TMS' (TSE:4891) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Dec 24TMS Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026TMS Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026
Price Target Changed • Oct 16Price target decreased by 18% to JP¥620Down from JP¥760, the current price target is provided by 1 analyst. New target price is 300% above last closing price of JP¥155. Stock is down 15% over the past year. The company is forecast to post a net loss per share of JP¥27.97 next year compared to a net loss per share of JP¥16.37 last year.
お知らせ • Aug 26TMS Co., Ltd. to Report Q2, 2026 Results on Oct 15, 2025TMS Co., Ltd. announced that they will report Q2, 2026 results on Oct 15, 2025
New Risk • Jul 22New major risk - Revenue and earnings growthEarnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Market cap is less than US$100m (JP¥7.49b market cap, or US$50.8m).
お知らせ • May 24TMS Co., Ltd. to Report Q1, 2026 Results on Jul 15, 2025TMS Co., Ltd. announced that they will report Q1, 2026 results on Jul 15, 2025
お知らせ • Apr 25TMS Co., Ltd. Submits CTN for Phase II/III Orion Study Japan Cohort of JX10 to PMDATMS Co., Ltd. announced that the Company has submitted a Clinical Trial Plan Notification (CTN) to the Pharmaceuticals and Medical Devices Agency ("PMDA") for ORION (Optimizing Reperfusion to Improve Outcomes and Neurologic Function), the global registrational study conducted by Corxel Pharmaceuticals Limited (CORXEL) including Japan cohort, that will investigate the effects of JX10 (also known as TMS-007) on functional recovery in acute ischemic stroke (AIS) patients, who present within 4.5 to 24 hours from "last known well". The impact of this matter on the Company's financial results of this fiscal year is minor.
Breakeven Date Change • Apr 14No longer forecast to breakevenThe analyst covering TMS no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of JP¥369.0m in 2026. New forecast suggests the company will make a loss of JP¥961.0m in 2028.
Breakeven Date Change • Apr 12No longer forecast to breakevenThe analyst covering TMS no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of JP¥369.0m in 2026. New forecast suggests the company will make a loss of JP¥961.0m in 2028.
お知らせ • Apr 11TMS Co., Ltd., Annual General Meeting, May 29, 2025TMS Co., Ltd., Annual General Meeting, May 29, 2025.
New Risk • Mar 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.1b net loss in 3 years). Market cap is less than US$100m (JP¥7.14b market cap, or US$48.1m).
お知らせ • Feb 26TMS Co., Ltd. to Report Fiscal Year 2025 Results on Apr 11, 2025TMS Co., Ltd. announced that they will report fiscal year 2025 results on Apr 11, 2025
分析記事 • Feb 21We Think TMS (TSE:4891) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
お知らせ • Feb 21TMS Co., Ltd. Provided Notice on the Status of JX10 (TMS-007) Clinical Trial Application in ChinaTMS Co., Ltd. announced that Corxel Pharmaceuticals announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the PRC (NMPA) has approved the Clinical Trial Application (CTA) for ORION (Optimizing Reperfusion to Improve Outcomes and Neurologic Function), the global registrational study including China cohort, that will investigate the effects of JX10 (TMS-007) on functional recovery in acute ischemic stroke (AIS) patients, who present within 4.5 to 24 hours from "last known well". The Company plans to participate in the global study as partner in Japan. About TMS-007(JX10) TMS-007 (JX10) is an investigational drug candidate for the treatment of acute cerebral infarction (AIS), and its mechanism of action is both thrombolytic and anti-inflammatory. The important thing in the treatment strategy for acute cerebral infarction is to restore blood flow as soon as possible after the onset of symptoms. TMS-007 (JX10) extends the short treatment period of administration within 4.5 hours after the onset of symptoms, which is the current standard of treatment, and may provide treatment opportunities to many patients. In a Phase II clinical trial conducted by our company in Japan, subjects administered TMS-007 (JX10) showed significantly improved clinical outcomes (no symptoms at all or symptoms but able to work without obvious impairment) after 90 days compared to placebo. This result was also confirmed by angiographic findings. TMS-007 (JX10) is currently undergoing a global study to further evaluate its efficacy and safety for the treatment of acute cerebral infarction by CORXEL.
お知らせ • Nov 27TMS Co., Ltd. to Report Q3, 2025 Results on Jan 14, 2025TMS Co., Ltd. announced that they will report Q3, 2025 results on Jan 14, 2025
分析記事 • Oct 24Here's Why We're Not Too Worried About TMS' (TSE:4891) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
New Risk • Oct 11New major risk - Revenue and earnings growthEarnings have declined by 35% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (JP¥7.38b market cap, or US$49.6m).
お知らせ • Aug 23TMS Co., Ltd. to Report Q2, 2025 Results on Oct 15, 2024TMS Co., Ltd. announced that they will report Q2, 2025 results on Oct 15, 2024
New Risk • Jul 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.4% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (JP¥10.2b market cap, or US$63.4m).
分析記事 • Jun 24We're Not Very Worried About TMS' (TSE:4891) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
お知らせ • Jun 19TMS Co., Ltd. Announces Dosing to the First Subject in TMS-008 Phase I Clinical TrialTMS Co., Ltd. announced that the first subject was dosed on June 19 in the Phase I clinical trial (Phase I single-dose, dose escalation study of TMS-008 in healthy adult male subjects; the Study) of TMS-008, which is being developed as a potential treatment for acute kidney injury. The results of previous non-clinical studies have confirmed the efficacy and safety of TMS-008 in the non-clinical phase of the study. In this Study, TMS-008 will be administered to healthy adult male subjects in escalating doses to confirm safety, tolerability, and pharmacokinetics in humans. The study will be conducted at the University of Tokyo Hospital. All subjects will be administered and observed by the end of this fiscal year, and the first readout is scheduled in the first quarter of fiscal year 2025. TMS-008 is a compound of SMTP (Stachybotrys microspora triprenyl phenol) family compounds derived from a type of black mold. The compound has strong anti-inflammatory and antioxidant activity by inhibiting soluble epoxide hydrolase (sEH) and is expected to have potential as a treatment for acute kidney injury.
お知らせ • May 27TMS Co., Ltd. to Report Q1, 2025 Results on Jul 12, 2024TMS Co., Ltd. announced that they will report Q1, 2025 results on Jul 12, 2024
お知らせ • Apr 14TMS Co., Ltd., Annual General Meeting, May 28, 2024TMS Co., Ltd., Annual General Meeting, May 28, 2024.
お知らせ • Mar 01TMS Co., Ltd. Submits Clinical Trial Plan Notification for TMS-008 Phase I Clinical Trial in JapanTMS Co., Ltd. announced that the Company has submitted a Clinical Trial Plan Notification to the Pharmaceuticals and Medical Devices Agency ("PMDA") to start Phase I clinical trial (the "Trial") for TMS-008, which is under development for acute kidney injury and other indications. This is the First-In-Human study of TMS-008, in which TMS-008 will be administered incrementally to healthy adult male subjects to evaluate the pharmacokinetics, pharmacodynamics, and safety of TMS-008. The Trial is scheduled to begin after a 30-day investigation period by the PMDA. TMS-008 is a small molecule compound belonging to the SMTP (stachybotrys microspora triprenyl phenol) compound family derived from black mold, as TMS-007/JX10, expected to have potential as a therapeutic agent for acute kidney injury (AKI) with its anti-inflammatory activity based on soluble epoxide hydrolase (sEH) inhibition as well as antioxidant activity. AKI is an indication in which renal function rapidly declines over a period of hours to days, and no drug has been approved for treatment of AKI to date. AKI can be caused by a variety of reasons, including cardiac surgery and drug side effects. In a study of patients who underwent coronary artery bypass surgery or heart valve surgery, 43% of patients developed acute kidney injury after surgery, and the mortality rate within 30 days was reported to be as high as 20%. Due to these, it is expected there is a significant unmet medical need for effective therapeutic agents for AKI. This matter will have no impact on the Company's financial results.
お知らせ • Feb 23TMS Co., Ltd. to Report Fiscal Year 2024 Results on Apr 12, 2024TMS Co., Ltd. announced that they will report fiscal year 2024 results on Apr 12, 2024
New Risk • Feb 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (JP¥11.3b market cap, or US$77.3m).
お知らせ • Feb 01TMS Co., Ltd. announced that it has received ¥684.324069 million in fundingOn January 31, 2024, TMS Co., Ltd. closed the transaction.
New Risk • Jan 17New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 23% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Market cap is less than US$100m (JP¥10.3b market cap, or US$69.7m).
お知らせ • Jan 13TMS Co., Ltd. announced that it expects to receive ¥684.324069 million in fundingTMS Co., Ltd. announced a private placement to issue 3,659,487 shares at a issue price 187 yen per share for a gross proceeds JPY 684,324,069 on January 11, 2024. The transaction included participation from RTW Master Fund, Ltd for 2,083,830 shares, RTW Innovation Master Fund, Ltd for 1,524,886 shares and RTW Biotech Opportunities Ltd for 50,771 shares. The transaction is expected to close on January 31, 2024.
お知らせ • Nov 23TMS Co., Ltd. to Report Q3, 2024 Results on Jan 15, 2024TMS Co., Ltd. announced that they will report Q3, 2024 results on Jan 15, 2024
New Risk • Oct 15New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: JP¥734m Forecast net loss in 3 years: JP¥325m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥325m net loss in 3 years). Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (JP¥9.04b market cap, or US$60.5m).
お知らせ • Aug 09TMS Co., Ltd. to Report Q2, 2024 Results on Oct 13, 2023TMS Co., Ltd. announced that they will report Q2, 2024 results on Oct 13, 2023
お知らせ • May 26TMS Co., Ltd. to Report Q1, 2024 Results on Jul 14, 2023TMS Co., Ltd. announced that they will report Q1, 2024 results on Jul 14, 2023
お知らせ • Nov 27TMS Co., Ltd. to Report Q3, 2023 Results on Jan 13, 2023TMS Co., Ltd. announced that they will report Q3, 2023 results on Jan 13, 2023
お知らせ • Nov 23TMS Co., Ltd. has completed an IPO in the amount of ¥2.499971 billion.TMS Co., Ltd. has completed an IPO in the amount of ¥2.499971 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,145,400 Price\Range: ¥670 Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,585,900 Price\Range: ¥670 Transaction Features: Rule 144A; Sponsor Backed Offering
